Premium
Front Cover: Mitochondria‐Targeting Selenophene‐Modified BODIPY‐Based Photosensitizers for the Treatment of Hypoxic Cancer Cells (ChemMedChem 22/2019)
Author(s) -
Karaman Osman,
Almammadov Toghrul,
Emre Gedik M.,
Gunaydin Gurcan,
Kolemen Safacan,
Gunbas Gorkem
Publication year - 2019
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201900617
Subject(s) - photosensitizer , front cover , photodynamic therapy , mitochondrion , cancer research , chemistry , bodipy , cancer cell , cancer , combinatorial chemistry , biophysics , biochemistry , medicine , cover (algebra) , photochemistry , biology , fluorescence , organic chemistry , physics , engineering , mechanical engineering , quantum mechanics
The Front Cover shows a conceptual view of how a logically designed near‐infrared absorbing photosensitizer (PS), BOD‐Se‐I , starts a series of photophysical processes which results in targeted destruction of mitochondria. BOD‐Se‐I was tested in detail in cell culture studies under both normoxic and hypoxic conditions. BOD‐Se‐I not only effectively functioned under hypoxic conditions due to effective mitochondria targeting ability but also showed highly selective photocytotoxicity towards cancer cells. To the best of our knowledge this marks the first example of a mitochondria‐targeted BODIPY PS that functions under hypoxic conditions. Hence, this material holds great promise towards realization of next‐generation photodynamic therapy drugs towards treatment of hypoxic solid tumors. More information can be found in the Communication by Gurcan Gunaydin, Safacan Kolemen, Gorkem Gunbas et al. on page 1879 in Issue 22, 2019 (DOI: 10.1002/cmdc.201900380).